BRÈVE

sur Bausch Health Companies Inc. (NASDAQ:BHC)

Bausch Health Announces Updates on Norwich XIFAXAN Litigation and New FDA Submission

Bausch Health Companies Inc., along with Salix Pharmaceuticals, provided an update concerning ongoing litigation with Norwich Pharmaceuticals and a new FDA submission by Norwich. The update follows the recent decision by the US Court of Appeals for the Federal Circuit on April 11, 2024. Both parties have filed petitions for a rehearing which is expected to be concluded within the next three months.

Norwich has informed Bausch Health of its submission to the FDA, seeking approval to market a generic version of XIFAXAN® 550 mg. Bausch Health has a 45-day window from the date of this notice to initiate a patent infringement lawsuit, which would delay FDA approval of the generic by up to 30 months or until a court decision. Bausch Health confirmed its commitment to vigorously defend its intellectual property rights for XIFAXAN®.

R. P.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Bausch Health Companies Inc.